Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
Reinhard Dummer, Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Helen Gogas(National and Kapodistrian University of Athens), Ana Arance(Hospital Clínic de Barcelona), Mario Mandalà(Ospedale Papa Giovanni XXIII), Gabriella Liszkay(National Institute of Oncology), Claus Garbe(University of Tübingen), Dirk Schadendorf(University Hospital Heidelberg), Ivana Krajsová(Charles University), Ralf Gutzmer(Medizinische Hochschule Hannover), Vanna Chiarion‐Sileni(Istituto Oncologico Veneto), Caroline Dutriaux(Hôpital Saint-André), Jan Willem B. de Groot(Isala), Naoya Yamazaki, Carmen Loquai(Johannes Gutenberg University Mainz), Laure A Moutouh-de Parseval(Novartis (Switzerland)), Michael D. Pickard(Array BioPharma (United States)), Victor Sandor(Array BioPharma (United States)), Caroline Robert(Université Paris-Sud), Keith T. Flaherty(Massachusetts General Hospital)
Cited by 584
Abstract
Related Papers
No related papers found
Powered by citation graph analysis